FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211894212> ?p ?o ?g. }

• W3211894212 abstract "A few studies have suggested that patients with inflammatory arthritis (IA) who remain persistent with subcutaneous TNF-α inhibitors (SC-TNFi) incur lower health care costs than patients who discontinue treatment, whereas data on the impact of non-persistence on indirect costs are largely lacking. Furthermore, existing estimates are based on fixed follow-ups, in relation to treatment initiation, and therefore do not measure costs in direct relation to treatment discontinuation. Therefore, by capturing costs in direct relation to treatment discontinuation, this study aimed to estimate direct and indirect costs associated with non-persistence with SC-TNFis in IA. Adult Swedish biologic-naïve IA patients initiating biologic treatment with a SC-TNFi (adalimumab, etanercept, certolizumab or golimumab) between May 6, 2010, and December 31, 2017, were identified in population-based registers with almost complete coverage. IA was defined as a diagnosis of rheumatic arthritis, ankylosing spondylitis/unspecified spondyloarthritis or psoriatic arthritis. Non-persistent patients were matched on propensity score to patients persistent with treatment by at least an additional 12 months. This enabled comparisons of direct healthcare costs and indirect costs for sick leave and disability pension, respectively, 12 months before and 12 months after treatment discontinuation. A balanced cohort of 486 matched pairs was generated. The total direct and indirect costs were significantly higher among non-persistent patients already during the 12 months before index ($20,802 [18,335–23,429] vs. $16,600 [14,331–18,696]). However, while non-persistent patients increased their total direct and indirect costs, persistent patients significantly decreased the same, further widening the difference in costs during the 12-month period after index date ($22,161 [19,754–24,556] vs. $13,465 [11,415–15,729]). Among biologic-naïve Swedish IA patients treated with SC-TNFis, persistent patients incurred about 40% lower aggregated direct and indirect costs compared to non-persistent patients the year following SC-TNFi discontinuation. This highlights the impact of treatment persistence from an economic viewpoint, adding further aspects to the clinical perspective." @default.
• W3211894212 created "2021-11-22" @default.
• W3211894212 creator A5015901006 @default.
• W3211894212 creator A5038829375 @default.
• W3211894212 creator A5042176392 @default.
• W3211894212 creator A5052244123 @default.
• W3211894212 creator A5054964075 @default.
• W3211894212 creator A5060308735 @default.
• W3211894212 creator A5081267338 @default.
• W3211894212 date "2021-11-09" @default.
• W3211894212 modified "2023-10-07" @default.
• W3211894212 title "Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA): A Retrospective Observational Study" @default.
• W3211894212 cites W1983081844 @default.
• W3211894212 cites W1989501575 @default.
• W3211894212 cites W1997771008 @default.
• W3211894212 cites W2008577611 @default.
• W3211894212 cites W2043124279 @default.
• W3211894212 cites W2124551692 @default.
• W3211894212 cites W2126049444 @default.
• W3211894212 cites W2129486471 @default.
• W3211894212 cites W2139062201 @default.
• W3211894212 cites W2139577967 @default.
• W3211894212 cites W2140148110 @default.
• W3211894212 cites W2148386211 @default.
• W3211894212 cites W2150291618 @default.
• W3211894212 cites W2166018731 @default.
• W3211894212 cites W2168021466 @default.
• W3211894212 cites W2171122996 @default.
• W3211894212 cites W2212767908 @default.
• W3211894212 cites W2264156726 @default.
• W3211894212 cites W2265946565 @default.
• W3211894212 cites W2289495056 @default.
• W3211894212 cites W2471354035 @default.
• W3211894212 cites W2474140472 @default.
• W3211894212 cites W2561458133 @default.
• W3211894212 cites W2735301415 @default.
• W3211894212 cites W2797837049 @default.
• W3211894212 cites W2808135930 @default.
• W3211894212 cites W2885320772 @default.
• W3211894212 cites W2911145951 @default.
• W3211894212 cites W2946295704 @default.
• W3211894212 cites W2965987895 @default.
• W3211894212 cites W3026969963 @default.
• W3211894212 cites W3092510769 @default.
• W3211894212 cites W3104380221 @default.
• W3211894212 cites W3196965483 @default.
• W3211894212 cites W48375751 @default.
• W3211894212 cites W62488812 @default.
• W3211894212 cites W84416910 @default.
• W3211894212 doi "https://doi.org/10.1007/s12325-021-01970-w" @default.
• W3211894212 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34751912" @default.
• W3211894212 hasPublicationYear "2021" @default.
• W3211894212 type Work @default.
• W3211894212 sameAs 3211894212 @default.
• W3211894212 citedByCount "1" @default.
• W3211894212 countsByYear W32118942122021 @default.
• W3211894212 crossrefType "journal-article" @default.
• W3211894212 hasAuthorship W3211894212A5015901006 @default.
• W3211894212 hasAuthorship W3211894212A5038829375 @default.
• W3211894212 hasAuthorship W3211894212A5042176392 @default.
• W3211894212 hasAuthorship W3211894212A5052244123 @default.
• W3211894212 hasAuthorship W3211894212A5054964075 @default.
• W3211894212 hasAuthorship W3211894212A5060308735 @default.
• W3211894212 hasAuthorship W3211894212A5081267338 @default.
• W3211894212 hasBestOaLocation W32118942121 @default.
• W3211894212 hasConcept C121955636 @default.
• W3211894212 hasConcept C126322002 @default.
• W3211894212 hasConcept C144133560 @default.
• W3211894212 hasConcept C17923572 @default.
• W3211894212 hasConcept C1862650 @default.
• W3211894212 hasConcept C198451711 @default.
• W3211894212 hasConcept C23131810 @default.
• W3211894212 hasConcept C2776260265 @default.
• W3211894212 hasConcept C2777077863 @default.
• W3211894212 hasConcept C2777226972 @default.
• W3211894212 hasConcept C2777575956 @default.
• W3211894212 hasConcept C2778715236 @default.
• W3211894212 hasConcept C2780132546 @default.
• W3211894212 hasConcept C2780289447 @default.
• W3211894212 hasConcept C2781290027 @default.
• W3211894212 hasConcept C2908647359 @default.
• W3211894212 hasConcept C6964187 @default.
• W3211894212 hasConcept C71924100 @default.
• W3211894212 hasConcept C99454951 @default.
• W3211894212 hasConceptScore W3211894212C121955636 @default.
• W3211894212 hasConceptScore W3211894212C126322002 @default.
• W3211894212 hasConceptScore W3211894212C144133560 @default.
• W3211894212 hasConceptScore W3211894212C17923572 @default.
• W3211894212 hasConceptScore W3211894212C1862650 @default.
• W3211894212 hasConceptScore W3211894212C198451711 @default.
• W3211894212 hasConceptScore W3211894212C23131810 @default.
• W3211894212 hasConceptScore W3211894212C2776260265 @default.
• W3211894212 hasConceptScore W3211894212C2777077863 @default.
• W3211894212 hasConceptScore W3211894212C2777226972 @default.
• W3211894212 hasConceptScore W3211894212C2777575956 @default.
• W3211894212 hasConceptScore W3211894212C2778715236 @default.
• W3211894212 hasConceptScore W3211894212C2780132546 @default.
• W3211894212 hasConceptScore W3211894212C2780289447 @default.
• W3211894212 hasConceptScore W3211894212C2781290027 @default.
• W3211894212 hasConceptScore W3211894212C2908647359 @default.

• next